Discovery of New Risk Markers for Ischemic Stroke Using a Novel Targeted Proteomics Chip

Background and Purpose— Emerging technologies have made it possible to simultaneously evaluate a large number of circulating proteins as potential new stroke risk markers. Methods— We explored associations between 85 cardiovascular proteins, assessed by a proteomics chip, and incident ischemic stroke in 2 independent cohorts of elderly (Prospective Investigation of the Vasculature in Uppsala Seniors [PIVUS]: n=977; 50% women, mean age=70.1 years, 71 fatal/nonfatal ischemic stroke events during 10.0 years; and Uppsala Longitudinal Study in Adult Men [ULSAM]: n=720, mean age=77.5 years, 75 ischemic stroke events during 9.5 years). The proteomics chip uses 2 antibodies for each protein and a polymerase chain reaction step to achieve a high-specific binding and the possibility to measure multiple proteins in parallel, but gives no absolute concentrations. Results— In PIVUS, 16 proteins were related to incident ischemic stroke using a false discovery rate of 5%. Of these, N-terminal pro-B-type natriuretic peptide (P=0.0032), adrenomedullin (P=0.018), and eosinophil cationic protein (P=0.0071) were replicated in ULSAM after adjustment for established stroke risk factors. In predefined secondary meta-analyses of individual data, interleukin-27 subunit &agr;, growth/differentiation factor 15, urokinase plasminogen activator surface receptor, tumor necrosis factor receptor superfamily member 6, macrophage colony-stimulating factor 1, and matrix metalloproteinase-7 were also potential risk markers for ischemic stroke after adjustment for multiple comparisons (P<0.0006). The addition of N-terminal pro-B-type natriuretic peptide, adrenomedullin, and eosinophil cationic protein to a model with established risk factors increased the C-statistic from 0.629 to 0.689 (P=0.001). Conclusions— Our data suggest that large-scale proteomics analysis is a promising way of discovering novel biomarkers that could substantially improve the prediction of ischemic stroke.

[1]  E. Ingelsson,et al.  Use of a proximity extension assay proteomics chip to discover new biomarkers for human atherosclerosis. , 2015, Atherosclerosis.

[2]  S. Moebus,et al.  B-type natriuretic peptide for incident atrial fibrillation-The Heinz Nixdorf Recall Study. , 2015, Journal of cardiology.

[3]  Bernadette A. Thomas,et al.  Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015, The Lancet.

[4]  Bernadette A. Thomas,et al.  Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015, The Lancet.

[5]  K. Kimura,et al.  Brain natriuretic peptide level on admission predicts recurrent stroke after discharge in stroke survivors with atrial fibrillation , 2014, Clinical Neurology and Neurosurgery.

[6]  C. Eaton,et al.  Improvement in Stroke Risk Prediction: Role of C-Reactive Protein and Lipoprotein-Associated Phospholipase A2 in the Women's Health Initiative , 2014, International journal of stroke : official journal of the International Stroke Society.

[7]  M. Christ-Crain,et al.  BNP but Not s-cTnln Is Associated with Cardioembolic Aetiology and Predicts Short and Long Term Prognosis after Cerebrovascular Events , 2014, PloS one.

[8]  V. Salomaa,et al.  Serum tissue-degrading proteinases and incident cardiovascular disease events , 2014, European journal of preventive cardiology.

[9]  V. Salomaa,et al.  Predictive value of midregional pro-adrenomedullin compared to natriuretic peptides for incident cardiovascular disease and heart failure in the population-based FINRISK 1997 cohort , 2014, Annals of medicine.

[10]  J. Stenvang,et al.  Homogenous 96-Plex PEA Immunoassay Exhibiting High Sensitivity, Specificity, and Excellent Scalability , 2014, PloS one.

[11]  T. Ueland,et al.  Matrix Metalloproteinase 7 Is Associated with Symptomatic Lesions and Adverse Events in Patients with Carotid Atherosclerosis , 2014, PloS one.

[12]  S. Moebus,et al.  B-type natriuretic peptide: distribution in the general population and the association with major cardiovascular and coronary events—The Heinz Nixdorf Recall Study , 2014, Clinical Research in Cardiology.

[13]  L. Lind,et al.  GDF-15 for Prognostication of Cardiovascular and Cancer Morbidity and Mortality in Men , 2013, PloS one.

[14]  P. Ward,et al.  Modulation of inflammation by interleukin‐27 , 2013, Journal of leukocyte biology.

[15]  N. Žarković,et al.  The dynamics of soluble Fas/APO 1 apoptotic biochemical marker in acute ischemic stroke patients. , 2013, Advances in medical sciences.

[16]  E. Ingelsson,et al.  Serum Endostatin and Risk of Mortality in the Elderly: Findings From 2 Community-Based Cohorts , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[17]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[18]  O. Melander,et al.  Adrenomedullin is a marker of carotid plaques and intima–media thickness as well as brachial pulse pressure , 2013, Journal of hypertension.

[19]  K. Node,et al.  Interleukin 27 inhibits atherosclerosis via immunoregulation of macrophages in mice. , 2013, American journal of physiology. Heart and circulatory physiology.

[20]  R. Schnabel,et al.  Association of MR-proadrenomedullin with cardiovascular risk factors and subclinical cardiovascular disease. , 2013, Atherosclerosis.

[21]  L. Lind,et al.  Mid-regional pro-atrial natriuretic peptide levels in the elderly: clinical and prognostic implications, and comparison to B-type natriuretic peptides. , 2013, Clinica chimica acta; international journal of clinical chemistry.

[22]  Biykem Bozkurt,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[23]  M. Burdick,et al.  Plasma CXCL12 Levels as a Predictor of Future Stroke , 2012, Stroke.

[24]  V. Andrés,et al.  Macrophage proliferation and apoptosis in atherosclerosis , 2012, Current opinion in lipidology.

[25]  D. Levy,et al.  Prognostic Utility of Novel Biomarkers of Cardiovascular Stress: The Framingham Heart Study , 2012, Circulation.

[26]  B. Fuhrman.  The urokinase system in the pathogenesis of atherosclerosis. , 2012, Atherosclerosis.

[27]  C. DeCarli,et al.  Multiple Biomarkers and Risk of Clinical and Subclinical Vascular Brain Injury: The Framingham Offspring Study , 2012, Circulation.

[28]  J. Hamilton,et al.  The TGF-β superfamily cytokine, MIC-1/GDF15: A pleotrophic cytokine with roles in inflammation, cancer and metabolism , 2011, Growth factors.

[29]  Martin Lundberg,et al.  Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood , 2011, Nucleic acids research.

[30]  Kenneth A Ellenbogen,et al.  2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2011, Journal of the American College of Cardiology.

[31]  S. Yusuf,et al.  Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study , 2010, The Lancet.

[32]  G. Niccoli,et al.  Eosinophil cationic protein: A new biomarker of coronary atherosclerosis. , 2010, Atherosclerosis.

[33]  Anders Larsson,et al.  Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. , 2008, The New England journal of medicine.

[34]  C. Björkelund,et al.  Asymmetric Dimethylarginine Independently Predicts Fatal and Nonfatal Myocardial Infarction and Stroke in Women: 24-Year Follow-Up of the Population Study of Women in Gothenburg , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[35]  L. Lind,et al.  Insulin sensitivity measured by the euglycaemic insulin clamp and proinsulin levels as predictors of stroke in elderly men , 2008, Diabetologia.

[36]  L. Lind,et al.  Metabolic Risk Factors for Stroke and Transient Ischemic Attacks in Middle-Aged Men: A Community-Based Study With Long-Term Follow-Up , 2006, Stroke.

[37]  J. Geng,et al.  The principal eosinophil peroxidase product, HOSCN, is a uniquely potent phagocyte oxidant inducer of endothelial cell tissue factor activity: a potential mechanism for thrombosis in eosinophilic inflammatory states. , 2006, Blood.

[38]  Lars Lind,et al.  A Comparison of Three Different Methods to Evaluate Endothelium-Dependent Vasodilation in the Elderly: The Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[39]  K. Huber,et al.  Association between plasmin activation system and intravascular ultrasound signs of plaque instability in patients with unstable angina and non-st-segment elevation myocardial infarction. , 2004, American heart journal.

[40]  S. Hazen,et al.  Effects of human mast cell tryptase and eosinophil granule proteins on the kinetics of blood clotting , 2003, American journal of hematology.

[41]  D. Tanné,et al.  Prospective Study of Serum Homocysteine and Risk of Ischemic Stroke Among Patients With Preexisting Coronary Heart Disease , 2003, Stroke.

[42]  D. Tanné,et al.  Soluble Intercellular Adhesion Molecule-1 and Risk of Future Ischemic Stroke: A Nested Case-Control Study From the Bezafibrate Infarction Prevention (BIP) Study Cohort , 2002, Stroke.

[43]  W. D. Fairlie,et al.  Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study , 2002, The Lancet.

[44]  K. Kohara,et al.  Soluble Fas ligand and atherosclerosis in hypertensive patients , 2002, Journal of hypertension.

[45]  W. Kannel.  Coronary heart disease risk factors in the elderly. , 2002, The American journal of geriatric cardiology.

[46]  H. Yoshimoto,et al.  Serum macrophage colony‐stimulating factor (M‐CSF) level is elevated in patients with old cerebral infarction related to vascular damage , 1999, American journal of hematology.

[47]  B. Sobel,et al.  Augmented urokinase receptor expression in atheroma. , 1995, Arteriosclerosis, thrombosis, and vascular biology.